Fexinidazole (Hoe239; Hoe-239) is a novel, potent and nitroimidazole-based antiparasitic agent that has been approved in 2021 by FDA as the first all-oral medication to treat African trypanosomiasis caused by Trypanosoma brucei gambiense. It is effective against both first and second stage disease. Some evidence also supports its use in Chagas disease.

纯度：≥98%

CAS：59729-37-2